Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples